For manufacturers entering the EU from the U.S. or China, one of the most common misconceptions is that clinical data generated for home-market approval will be sufficient for CE marking under the EU MDR. In practice, clinical strategies that were acceptable to the FDA or NMPA often do not meet EU expectations.
In this blog, we explain how clinical evidence is assessed under the EU MDR and where non-EU manufacturers typically underestimate requirements.
Clinical Evaluation Is a Continuous Process
Under the MDR, clinical evaluation is not a one-time activity but a continuous, lifecycle-driven process. Clinical evidence, established through the systematic evaluation of all available clinical data, must:
- Support the intended purpose and claims
- Demonstrate safety and performance
- Be sufficient, relevant, and of appropriate scientific quality
- Reflect the state of the art (SOTA)
- Maintain a continuously favourable benefit–risk profile
- Be continuously updated throughout the device lifecycle
The MDR does not define a fixed threshold for what constitutes "sufficient" clinical evidence. Instead, sufficiency must be justified through a qualified assessment, taking into account both the quantity and quality of the available data.
Three Routes, Very Different Rules
The EU MDR requires manufacturers to define and justify their clinical evidence strategy. The three main routes are:
- Exemption from the generation of clinical data
- Clinical data related to an equivalent device
- Clinical data from the device under evaluation
Exemption
Under the MDR, there is no true exemption pathway. Article 61(10) allows for a limited number of devices to rely on non-clinical data only. Even in these cases, the EU mandates a formal Clinical Evaluation Report (CER), a requirement not shared by the FDA for most 510(k) submissions.
Equivalence
The EU MDR and NMPA often require formal agreements granting full access to a competitor's technical documentation, particularly for Class III and implantable devices. The FDA's 510(k) process does not require such agreements. Under the EU MDR, equivalence is most feasible when applied to devices from the same manufacturer.
Clinical Data from the Device Under Evaluation
Under the EU MDR (Articles 61(4)–(6)), clinical investigations are a default requirement for implantable and Class III devices, with very few exceptions. Trials that might not be required in other regions are often unavoidable in the EU.
Can You Reuse Your Existing Data?
Reusing available clinical data can reduce development timelines and costs, provided that the data are sufficient to demonstrate conformity with the General Safety and Performance Requirements (GSPR). The acceptability of foreign clinical data is never guaranteed and must always be justified.
Under the EU MDR, data quality goes beyond scientific rigor alone. It includes relevance, reliability, transparency, and applicability to the intended European use context.
Notified Bodies routinely assess whether differences in clinical practice, standard of care, or patient characteristics limit the applicability of data generated outside Europe. Manufacturers should explicitly assess these differences and document whether they could influence device performance or safety under European conditions.
Where limitations or residual uncertainties are identified, manufacturers are expected to justify data applicability or generate proportionate additional evidence — for example through targeted PMCF or bridging activities.
PMCF as a Strategic Tool
Where pre-market clinical data cannot fully demonstrate applicability to the European context, Post-Market Clinical Follow-up (PMCF) plays an important role in bridging remaining data gaps.
PMCF is not a corrective afterthought, but a planned and continuous activity that supports clinical evidence throughout the device lifecycle. Under the MDR, PMCF is mandatory for all device classes.
Used proactively, PMCF allows manufacturers to:
- Confirm device performance in the EU population
- Assess the impact of practice- or population-related differences
- Progressively reduce residual uncertainty
Looking to Go Deeper?
Understanding clinical evidence under the EU MDR requires more than aligning datasets — it requires a structured, lifecycle-driven approach to data, strategy, and regulatory expectations.
Download the QbD Group whitepaper "Home Market Approval ≠ EU Readiness" to explore the key clinical and regulatory gaps and how to address them.
关于作者
PhD Physics, MSc Medical Physics · Business Unit Manager RA MD
Anne-Sophie is a Regulatory Affairs leader with over two decades of experience in medical physics, diagnostic imaging, and medical device regulation. She supports clients navigating EU MDR, FDA, and international regulatory frameworks.
关于作者
Business Unit Manager Medical Affairs
12 years of experience in the medical device field. Expert in clinical evidence and medical writing for Class I to Class III devices, including MDSW and AI-driven MDSW, as well as safety management in clinical investigations.
Watch the Webinar: Entering the European MedTech Market
Why one approval doesn't fit all — discover where FDA and NMPA logic breaks down under EU MDR, and how to build a defensible market-entry strategy.
Watch the webinar订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
